µÏÍþ¹ú¼Ê

µÏÍþÖƵÏÍþ¹ú¼Ê µÏÍþÖƵÏÍþ¹ú¼Ê

¼ò ¤™
  • ¼ò
  • ·±
  • EN
¤œ
Ïà¹ØÁ´½Ó
  • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
ÐÂÎÅ·¢²¼
Press Release
Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
µÏÍþÖƵÏÍþ¹ú¼Ê | æÚÀ´ÃÀ?ÔÙ»ñ¹ú¼Ò»ù²ãÌÇÄò²¡·ÀÖιÜÀíÖ¸ÄÏÍƼö
·¢²¼ÈÕÆÚ£º2025/12/22
×ÖºÅ

½üÈÕ£¬¡¶ÖлªÄÚ¿ÆÔÓÖ¾¡··¢²¼¡¶¹ú¼Ò»ù²ãÌÇÄò²¡·ÀÖιÜÀíÖ¸ÄÏ£¨2025£©¡·£¨ÒÔϼò³ÆÖ¸ÄÏ£©£¬Ö¼ÔÚÍƶ¯»ù²ãÌÇÄò²¡½¡¿µ¹ÜÀí¹¤×÷µÄ¹æ·¶»¯[1]¡£µÏÍþÖƵÏÍþ¹ú¼ÊÊ׸öÖйúÔ­ÑÐGLP-1RAÖÜÖƼÁæÚÀ´ÃÀ?£¨¾ÛÒÒ¶þ´¼ÂåÈûÄÇëÄ×¢ÉäÒº£©±»ÄÉÈëÖ¸ÄÏ£¬ÕâÊǼÌ2022Äê°æ[2]Ö®ºóÔٶȻñµÃÕâÒ»¹ú¼Ò¼¶ÖØ°õÖ¸ÄϵÄÈÏ¿É¡£


½üÄêÀ´£¬æÚÀ´ÃÀ?·¢±íÁËһϵÁÐÁÙ´²¼°»ù´¡Ñо¿Ö¤¾Ý£¬Õ¹ÏÖ³öÔÚѪÌÇƽÎÈ¿ØÖÆ¡¢ÐÄÄÔѪ¹Ü±£»¤¡¢ÉöÔ༰¸ÎÔàµÈ¶à·½ÃæµÄ×ۺϻñÒæ¡£¶àÖÐÐÄÕæʵÊÀ½çÑо¿ÏÔʾ£¬æÚÀ´ÃÀ?ÔÚ¸ÄÉÆÆÏÌÑÌÇÄ¿±ê·¶Î§Ê±¼ä£¨TIR£¬Ò»ÖÖѪÌÇ¿ØÖƵıê×¼Ö¸±ê£©·½ÃæÏà±ÈGLP-1RAÈÕÖƼÁÀûÀ­Â³ëĸü¾ßÓÅÊÆ[3]¡£ÁíÒ»ÏîËæ»ú¿ª·Å¶ÔÕÕÊÔÑé֤ʵ£¬¶þ¼×Ë«ëÒ»ù´¡ÉÏÁªºÏæÚÀ´ÃÀ?ÔÚ¸ÄÉÆѪÌÇ¿ØÖƼ°Í¨¹ý³ÖÐøÆÏÌÑÌǼà²â£¨CGM£©ÆÀ¹ÀµÄѪÌDZäÒìÐÔ·½Ã棬Ч¹ûÓÅÓڸʾ«ÒȵºËØ[4]¡£ÕâЩÑо¿±íÃ÷æÚÀ´ÃÀ?Äܹ»ÊµÏÖѪÌǵÄƽÎÈ¿ØÖÆ£¬¼õÉÙѪÌDz¨¶¯¼°ÆäÏà¹Ø²»Á¼Ê¼þ¡£

Ê׸öÕë¶ÔÖйúÈËȺµÄGLP-1RAÐÄѪ¹Ü½á¾Ö´óÐÍÕæʵÊÀ½çÑо¿£¨FLYINGÑо¿£©Ö¤ÊµÁËæÚÀ´ÃÀ?³¤ÆÚÖÎÁÆÄܹ»´øÀ´ÏÔÖøµÄÐÄѪ¹Ü»ñÒ棬Ïà±ÈʹÓ÷dz¦´ÙÒȵºËؽµÌǵÏÍþ¹ú¼ÊÖÎÁÆÄܹ»ÏÔÖø½µµÍ3P-MACE£¨°üÀ¨·ÇÖÂËÀÐÔÐļ¡¹£ËÀ¡¢·ÇÖÂËÀÐÔ×äÖлòÐÄѪ¹ÜËÀÍö£©·çÏÕ32%[5]¡£Ëæ»ú¶ÔÕÕÑо¿Ö¤ÊµæÚÀ´ÃÀ?¸ÄÉÆÌÇÄò²¡Éö²¡£¨DKD£©»¼ÕßÄòµ°°×ÓëÒ»ÏßSGLT2ÒÖÖƼÁ´ï¸ñÁо»Ï൱£¬ÌáʾÆäÔÚ½µÌǵÄͬʱ»¹ÓÐÖúÓÚÑÓ»ºÉö²¡½øÕ¹[6]¡£Ò»Ð©ÁÙ´²Óë»ù´¡Ñо¿±íÃ÷æÚÀ´ÃÀ?Äܹ»ÓÐЧ¼õÉÙÄÚÔàÖ¬·¾Ãæ»ý£¨VFA£©¡¢¸ÄÉÆÖ¬·¾¸Î²¢±£»¤¸ÎÔà[7-9]¡£

´ÓȨÍþÖ¸ÄϵijÖÐøÈÏ¿É£¬µ½¸Ä±äÁÙ´²Êµ¼ùµÄÐÄÉö¸ÎµÈ»ñÒæÖ¤¾Ý£¬æÚÀ´ÃÀ?Õýƾ½èÔúʵµÄ¿ÆÑÐÊý¾Ý£¬Îª2ÐÍÌÇÄò²¡ÖÎÁÆÌṩ¸üÈ«ÃæµÄÑ¡Ôñ¡£Ëæ×ÅÔÚ»ù²ãÒ½ÁÆ»ú¹¹µÄ¹ã·ºÓ¦Óã¬æÚÀ´ÃÀ?ÓÐÍû»Ý¼°¸ü¹ã·ºµÄÖйúÌÇÄò²¡»¼Õߣ¬Îª½µµÍÌÇÄò²¡²¢·¢Ö¢¸ºµ£¡¢ÖúÁ¦¡°½¡¿µÖйú2030¡±ºêΰÀ¶Í¼¹±Ï×ÖØÒªÁ¦Á¿¡£

²Î¿¼ÎÄÏ×£º

²Î¿¼ÎÄÏ×£º

[1]Jun Chen,et al.Efficacy and safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in patients with hepatitis B cirrhosis: a retroprospective observational study. EASL 2025.Abstract No: SAT-258.

[2]Xiaochuan Diao,et al.Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide and entecavir in the hepatitis B virus related acute-on-chronic liver failure patients: a single-centre retrospective study. EASL 2025.Abstract No: WED-295

[3]Shu Xiong,et al.Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment.EASL 2025.Abstract No: SAT-321

²Î¿¼ÎÄÏ×£º

[1]Jun Chen,et al.Efficacy and safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in patients with hepatitis B cirrhosis: a retroprospective observational study. EASL 2025.Abstract No: SAT-258.

[2]Xiaochuan Diao,et al.Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide and entecavir in the hepatitis B virus related acute-on-chronic liver failure patients: a single-centre retrospective study. EASL 2025.Abstract No: WED-295

[3]Shu Xiong,et al.Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment.EASL 2025.Abstract No: SAT-321

²Î¿¼ÎÄÏ×£º

[1]Jun Chen,et al.Efficacy and safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in patients with hepatitis B cirrhosis: a retroprospective observational study. EASL 2025.Abstract No: SAT-258.

[2]Xiaochuan Diao,et al.Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide and entecavir in the hepatitis B virus related acute-on-chronic liver failure patients: a single-centre retrospective study. EASL 2025.Abstract No: WED-295

[3]Shu Xiong,et al.Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment.EASL 2025.Abstract No: SAT-321

²Î¿¼ÎÄÏ×£º

[1]Jun Chen,et al.Efficacy and safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in patients with hepatitis B cirrhosis: a retroprospective observational study. EASL 2025.Abstract No: SAT-258.

[2]Xiaochuan Diao,et al.Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide and entecavir in the hepatitis B virus related acute-on-chronic liver failure patients: a single-centre retrospective study. EASL 2025.Abstract No: WED-295

[3]Shu Xiong,et al.Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment.EASL 2025.Abstract No: SAT-321

²Î¿¼ÎÄÏ×

²Î¿¼ÎÄÏ×

²Î¿¼ÎÄÏ×£º

[1]Jun Chen,et al.Efficacy and safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in patients with hepatitis B cirrhosis: a retroprospective observational study. EASL 2025.Abstract No: SAT-258.

[2]Xiaochuan Diao,et al.Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide and entecavir in the hepatitis B virus related acute-on-chronic liver failure patients: a single-centre retrospective study. EASL 2025.Abstract No: WED-295

[3]Shu Xiong,et al.Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment.EASL 2025.Abstract No: SAT-321

²Î¿¼ÎÄÏ×£º

[1]Jun Chen,et al.Efficacy and safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in patients with hepatitis B cirrhosis: a retroprospective observational study. EASL 2025.Abstract No: SAT-258.

[2]Xiaochuan Diao,et al.Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide and entecavir in the hepatitis B virus related acute-on-chronic liver failure patients: a single-centre retrospective study. EASL 2025.Abstract No: WED-295

[3]Shu Xiong,et al.Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment.EASL 2025.Abstract No: SAT-321

²Î¿¼ÎÄÏ×£º

[1]Jun Chen,et al.Efficacy and safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in patients with hepatitis B cirrhosis: a retroprospective observational study. EASL 2025.Abstract No: SAT-258.

[2]Xiaochuan Diao,et al.Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide and entecavir in the hepatitis B virus related acute-on-chronic liver failure patients: a single-centre retrospective study. EASL 2025.Abstract No: WED-295

[3]Shu Xiong,et al.Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment.EASL 2025.Abstract No: SAT-321

²Î¿¼ÎÄÏ×£º

[1]Jun Chen,et al.Efficacy and safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in patients with hepatitis B cirrhosis: a retroprospective observational study. EASL 2025.Abstract No: SAT-258.

[2]Xiaochuan Diao,et al.Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide and entecavir in the hepatitis B virus related acute-on-chronic liver failure patients: a single-centre retrospective study. EASL 2025.Abstract No: WED-295

[3]Shu Xiong,et al.Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment.EASL 2025.Abstract No: SAT-321

[1]Jun Chen,et al.Efficacy and safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in patients with hepatitis B cirrhosis: a retroprospective observational study. EASL 2025.Abstract No: SAT-258.

[2]Xiaochuan Diao,et al.Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide and entecavir in the hepatitis B virus related acute-on-chronic liver failure patients: a single-centre retrospective study. EASL 2025.Abstract No: WED-295

[3]Shu Xiong,et al.Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment.EASL 2025.Abstract No: SAT-321

²Î¿¼ÎÄÏ×£º

[1]Jun Chen,et al.Efficacy and safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in patients with hepatitis B cirrhosis: a retroprospective observational study. EASL 2025.Abstract No: SAT-258.

[2]Xiaochuan Diao,et al.Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide and entecavir in the hepatitis B virus related acute-on-chronic liver failure patients: a single-centre retrospective study. EASL 2025.Abstract No: WED-295

[3]Shu Xiong,et al.Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment.EASL 2025.Abstract No: SAT-321


²Î¿¼ÎÄÏ×£º

[1]ÖлªÄÚ¿ÆÔÓÖ¾.2025.64(12):1169-1186

[2]ÖлªÄÚ¿ÆÔÓÖ¾,2022,61(3):249-262.

[3]Front Pharmacol. 2024 Mar 7;15:1370594.

[4]Front Pharmacol. 2023 May 4;14:1171399.

[5]MedComm (2020). 2025;6(2):e70094.

[6]Front. Endocrinol. 2024.15:1387993.

[7]ɽ¶«Ò½µÏÍþ¹ú¼Ê,2022,62(25):35-38.

[8]Front Endocrinol (Lausanne). 2023 Jan 26;14:1106868.

[9]Front Pharmacol. 2021 Dec 6;12:781856.

¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê

µÏÍþÖƵÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬ÏÂÊôºÀÉ­µÏÍþ¹ú¼ÊÒµ¡¢³£Öݺã°îµÏÍþ¹ú¼ÊÒµ¡¢µÏÍþÉúÎïÒ½µÏÍþ¹ú¼ÊµÈ×Ó¹«Ë¾£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£½ØÖÁÄ¿Ç°£¬¹«Ë¾ÔÚÖйú²úÉúÏúÊÛÊÕÈëµÄ´´ÐµÏÍþ¹ú¼Ê¹²7¿î£¬ÐγÉÁ˷ḻµÄ²úÆ·¹ÜÏß¡£µÏÍþÖƵÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖƵÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖصã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£µÏÍþÖƵÏÍþ¹ú¼ÊÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£

ÃâÔðÉùÃ÷

±¾ÎĽö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍƼö¡£±¾ÎÄÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£

Ç°Õ°ÐÔ˵Ã÷

±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æ丽Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆΪ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖƵÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄÜ°üÀ¨ÓëµÏÍþÖƵÏÍþ¹ú¼ÊÒµÎñºÍ²úÆ·Ç°¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆںͲßÂÔÏà¹ØµÄÇ°Õ°ÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍƲâÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿Æѧ¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾­¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËغܶ඼ÊǵÏÍþÖƵÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊƲ»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖƵÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζ­Ê¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄÇ°Õ°ÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£

¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿